文献速递肾小球疾病

皮质类固醇治疗IgA肾病支持替代终点的证据

Supportive Evidence of Surrogate End Points Based on Treatment Effect of Corticosteroid in IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2025-09-09

基于日本IgA肾病队列,采用重叠权重平衡基线后分析皮质类固醇暴露与肾脏结局的关系。结果显示激素治疗与复合肾脏结局发生率更低、eGFR下降更慢及蛋白尿减少更多相关,支持eGFR斜率与蛋白尿减少作为替代终点。

要点

  • 激素治疗与复合肾脏结局风险更低相关(5.3% vs 13.1%,P=0.0485)。
  • 激素组eGFR年下降斜率更缓(-0.32 vs -2.95 ml/min/1.73m²/yr,P=0.01)。
  • 激素组1年蛋白尿降幅更大(-76.5% vs -48.0%,P<0.001)。

核心结论

  • eGFR斜率与蛋白尿减少在激素治疗背景下与肾脏结局强且一致相关,支持其作为临床试验替代终点。

研究设计与样本

  • 日本IgA肾病队列研究,纳入活检证实的IgA肾病患者,按诊断12个月内皮质类固醇暴露分组,采用重叠权重平衡基线特征。

主要发现

  • 激素治疗与复合肾脏结局发生率更低相关(5.3% vs 13.1%,P=0.0485)。
  • 激素组eGFR年下降斜率更缓(-0.32 vs -2.95 ml/min/1.73m²/yr,P=0.01)。
  • 激素组1年蛋白尿降幅更大(-76.5% vs -48.0%,P<0.001)。

临床怎么用

  • eGFR斜率与蛋白尿减少可用于常规肾脏病实践中的风险分层与治疗监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Estimated glomerular filtration rate (eGFR) slope and proteinuria reduction have been proposed as surrogate end points for kidney outcomes in IgA nephropathy (IgAN), but their validity remains under debate. We aimed to evaluate the surrogate potential of these markers in the context of corticosteroid therapy within a large Japanese cohort. METHODS: Patients with biopsy-proven IgAN from the Japan IgA Nephropathy Cohort Study were analyzed. Patients were categorized based on corticosteroid exposure within 12 months of diagnosis. To minimize confounding, overlap weighting was used to balance baseline characteristics. The primary outcome was a composite kidney end point defined as a ≥ 40 decline in eGFR or the initiation of kidney replacement therapy. Secondary outcomes included 2-year eGFR slope and proteinuria reduction at 1-year. RESULTS: Corticosteroid therapy was associated with a lower incidence of the composite kidney outcome (5.3 vs. 13.1%, P = 0.0485), slower decline in eGFR (-0.32 vs. -2.95 ml/min per 1.73 m2/yr, P = 0.01), and greater proteinuria reduction (-76.5% vs. -48.0%, P < 0.001). CONCLUSION: Both the eGFR slope and proteinuria reduction demonstrated strong and consistent associations with kidney outcomes in the context of corticosteroid therapy. These findings support their effectiveness as surrogate end points for clinical trials and suggest their usefulness for risk stratification and therapeutic monitoring in routine nephrology practice.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sasaki T, Tsuboi N, Koike K, et al. Supportive Evidence of Surrogate End Points Based on Treatment Effect of Corticosteroid in IgA Nephropathy. Kidney Int Rep. 2025. PMID: 41502805. doi:10.1016/j.ekir.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。